Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium Species

6 Apr 2010

Abstract excerpt

The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20368403
DOI: 10.1128/aac.01545-09

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium SpeciesPMID 20368403Read ↗

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New FluoroquinoloneSemantic proximity Read ↗

In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.Semantic proximity Read ↗

Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.Semantic proximity Read ↗

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice modelsSemantic proximity Read ↗

In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera.Semantic proximity Read ↗

In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.Semantic proximity Read ↗

Anti-Mycobacterial Activity of Marine Fungus-Derived 4-Deoxybostrycin and NigrosporinSemantic proximity Read ↗

Activities of Linezolid against Rapidly Growing MycobacteriaSemantic proximity Read ↗

New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains.Semantic proximity Read ↗

Antibacterial Activity of DC-159a Against Salmonella Typhimurium.Semantic proximity Read ↗

Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.